MR contrast agent developer Epix Medical has appointed Dr. Andrew Uprichard to the position of president and chief operating officer.
Uprichard most recently was COO of ArQule, where he initiated a strategy that helped transform the firm from a chemistry platform company to a drug discovery and development organization, according to Cambridge, MA-based Epix.
By AuntMinnie.com staff writersJuly 16, 2004
Related Reading
Epix testing MS-325 for cardiac imaging, July 12, 2004
Epix launches new MS-325 trial, July 8, 2004
Schering submits MS-325 for EU approval, June 7, 2004
Epix raises $96 million, June 4, 2004
Epix floats new debt, June 2, 2004
Copyright © 2004 AuntMinnie.com
